Rheogene, Inc.
Records under this name other than the patents Rheogene, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,715,959 | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system Term ended Ended no later than Nov 6, 2025 · Medium confidence | Term ended | Ended no later than Nov 6, 2025 | Medium confidence |
| US 7,456,315 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex Term ended Ended no later than Apr 22, 2025 · Medium confidence | Term ended | Ended no later than Apr 22, 2025 | Medium confidence |
| US 9,493,540 | Novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system Formerly held Lapsed on the fee record Ended Nov 15, 2024 · High confidence | Lapsed on the fee record | Ended Nov 15, 2024 | High confidence |
| US 8,691,527 | Substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system Formerly held Term ended Term ended Aug 19, 2024 · From the USPTO record | Term ended | Term ended Aug 19, 2024 | From the USPTO record |
| US 7,375,093 | Ketone Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex Term ended Term ended Mar 14, 2024 · High confidence | Term ended | Term ended Mar 14, 2024 | High confidence |
| US 8,129,355 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex Lapsed on the fee record Ended Mar 6, 2024 · From the USPTO record | Lapsed on the fee record | Ended Mar 6, 2024 | From the USPTO record |
| US 7,563,928 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex Term ended Ended no later than Feb 26, 2024 · From the USPTO record | Term ended | Ended no later than Feb 26, 2024 | From the USPTO record |
| US 8,524,948 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex Term ended Ended no later than Feb 26, 2024 · From the USPTO record | Term ended | Ended no later than Feb 26, 2024 | From the USPTO record |
| US 9,255,273 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex Lapsed on the fee record Ended Feb 9, 2024 · From the USPTO record | Lapsed on the fee record | Ended Feb 9, 2024 | From the USPTO record |
| US 9,249,207 | Novel substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system Formerly held Lapsed on the fee record Ended Feb 2, 2024 · High confidence | Lapsed on the fee record | Ended Feb 2, 2024 | High confidence |